Methods and compositions using Klotho-FGF fusion polypeptides

Patent metadata

Field	Value
Publication number	US-9458209-B2
Application number	US-201313904574-A
Country	US
Kind code	B2
Filing date	May 29, 2013
Priority date	Jan 28, 2008
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

The present invention is directed to fusion polypeptides comprising a Klotho protein or an active fragment thereof and FGF23 or an active fragment thereof.

First claim

What is claimed is:

1. A fusion polypeptide comprising, in order from N-terminus to C-terminus, a polypeptide comprising the sequence of amino acids 34 to 982 of SEQ ID NO: 19; one or more linkers; and a polypeptide comprising the sequence of amino acids 1000 to 1228 of SEQ ID NO: 19,
wherein the fusion polypeptide is capable of activating Egr-1.

2. The fusion polypeptide of claim 1 , further comprising a signal peptide.

3. A pharmaceutical composition comprising the fusion polypeptide of claim 1 and a pharmaceutically acceptable carrier.

4. The fusion polypeptide of claim 1 , wherein the one or more linkers comprise one or more polypeptide linkers.

5. A nucleic acid comprising a sequence that encodes a fusion polypeptide comprising, in order from N-terminus to C-terminus, a polypeptide comprising the sequence of amino acids 34 to 982 of SEQ ID NO: 19; one or more linkers; and a polypeptide comprising the sequence of amino acids 1000 to 1228 of SEQ ID NO: 19,
wherein the fusion polypeptide is capable of activating Egr-1.

6. A host cell containing the nucleic acid of claim 5 .

7. A vector comprising the nucleic acid of claim 5 .

8. A fusion polypeptide comprising, in order from N-terminus to C-terminus, a polypeptide consisting of the sequence of amino acids 34 to 982 of SEQ ID NO: 19; one or more linkers; and a polypeptide consisting of the sequence of amino acids 1000 to 1228 of SEQ ID NO: 19,
wherein the fusion polypeptide is capable of activating Egr-1.

9. The fusion polypeptide of claim 8 , wherein the one or more linkers comprise one or more polypeptide linkers.

10. The fusion polypeptide of claim 8 , further comprising a signal peptide.

11. A pharmaceutical composition comprising the fusion polypeptide of claim 8 and a pharmaceutically acceptable carrier.

Assignees

• Novartis Ag

Inventors

• Glass David
• Hu Shou-Ih

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title